Investigating the Spreading Uptake of Sacubitril/Valsartan Across the US

In a study published in our December issue, researchers analyzed how prescribing of the newly approved heart failure drug sacubitril/valsartan diffused across the nation.

When new drugs are approved by the FDA, they can take time to diffuse across the population as clinicians begin to prescribe them. Uptake is not always quick or uniform, due to reasons that can include clinical inertia, provider familiarity, and the cost to patients.

On this episode of Managed Care Cast, we’re talking with the lead author of a study published in our December 2021 issue. The article, “Variation in Early Diffusion of Sacubitril/Valsartan and Implications for Understanding Novel Drug Diffusion,” describes how prescribing of the newly approved heart failure drug spread across the nation. Joining us today is Lauren Gilstrap, MD, MPH, of Dartmouth-Hitchcock Medical Center and The Dartmouth Institute for Health Policy and Clinical Practice.

Listen above or through one of these podcast services:


Related Videos
Jeremy Wigginton, MD
Screenshot of Eva Parker, MD, smiling during an interview
Screenshot of Eleonora Lad, MD, PhD, smiling
Debra Patt, MD, PhD, MBA, Executive Vice President, Texas Oncology
Related Content
© 2023 MJH Life Sciences
All rights reserved.